Table 1.
Study cohort demographics.
| Bronchoscopy cohort (n=34) | ||
|---|---|---|
| COPD+ | COPD- | |
| N | 18 | 16 |
| Age (median, IQR) | 56 (52-63) | 57 (53-61) |
| Females, % | 22% | 13% |
| Smoking status | - | - |
| Current, % | 61% | 19% |
| Former, % | 28% | 50% |
| Never, % | 6% | 25% |
| Smoking pack-year history | 38 (30-49) | 4.50 (0-23) |
| Race (Caucasian), % | 94% | 100% |
| BMI (KG/M2) | 24.06 (19.16-26.68) | 26.81 (23.09-27.52) |
| FEV1, ML | 2655 (1925-3058) | 2870 (2710-3550) |
| FEV1, % | 76.30% (58.00-91.05) | 85.00% (81.00-92.00) |
| FVC, ML | 3940 (3245-4765) | 4010 (3550-4710) |
| FVC, % | 90.95% (78.75-102.50) | 87.00% (81.40-103.00) |
| FEV1/FVC, % | 67.04% (60.38-75.53) | 75.00% (71.51-80.65) |
| Undetectable HIV viral load, % | 89% | 63% |
| CD4 cell count (cells/MM3) | 450 (260-510) | 460 (110-620) |
| On ART, % | 94% | 81% |
| On ICS, % | 22% | 19% |
| Start cohort (n=378) | ||
|---|---|---|
| Airflow obstruction (FEV1/FVC<LLN) | No airflow obstruction (FEV1/FVC≥LLN) | |
| N | 31 | 347 |
| Age (mean ± SD) | 40 (34-49) | 37 (31-54) |
| Females, % | 9.68% | 8.07% |
| Smoking status | ||
| Current, % | 61% | 44% |
| Former, % | 6% | 20% |
| Never, % | 32% | 36% |
| Pack-year history | 5 (0-23) | 2 (0-9) |
| Race | ||
| Black, % | 19% | 18% |
| Asian, % | 0% | 1% |
| Caucasian, % | 68% | 62% |
| Hispanic, % | 10% | 17% |
| Other, % | 3% | 2% |
| BMI (KG/M2) | 24.11 (22.21-26.36) | 24.49 (22.41-27.50) |
| FEV1, ML | 3120 (2445-3795) | 3830 (3350- 4330) |
| FEV1, % Predicted | 81.68% (69.29-90.41) | 96.64% (88.88-104.14) |
| FVC, ML | 4910 (3740-5790) | 4690 (4125-5345) |
| FVC, % Predicted | 97.70% (86.21-108.52) | 95.95% (88.10-103.59) |
| FEV1/FVC Ratio | 0.6731 (0.6470- 0.6913) | 0.8193 (0.7815- 0.8581) |
| Hepatitis C | 3% | 4% |
| Hypertension | 0% | 10% |
| CD4 cells/MM3 | 655.0 (580.5- 719.8) | 637.5 (585.0-740.0) |
| HIV RNA viral load, copies/MM3 | 20200 (4856- 60598) | 17090 (4456-56402) |
ART: antiretroviral therapy BMI: body mass index. ICS: Inhaled corticosteroids. SD: standard deviation. Spirometry corresponds to pre-bronchodilator measurements. Median and interquartile range are shown for non-normally distributed variables. Race was based on participant's self-assessment.